☰

Sergey V. Karakashev - Publications

Affiliations: 
2011-2015 Biochemistry Drexel University College of Medicine, Philadelphia, PA, United States 
Tree Info Grants Similar researchers PubMed Report error

15 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2022 Liu H, Lin J, Zhou W, Moses R, Dai Z, Kossenkov AV, Drapkin R, Bitler BG, Karakashev S, Zhang R. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. Cancer Immunology Research. OF1-OF11. PMID 35726891 DOI: 10.1158/2326-6066.CIR-22-0088  0.349
2021 Lin J, Liu H, Fukumoto T, Zundell J, Yan Q, Tang CA, Wu S, Zhou W, Guo D, Karakashev S, Hu CA, Sarma K, Kossenkov AV, Zhang R. Targeting the IRE1α/XBP1s pathway suppresses CARM1-expressing ovarian cancer. Nature Communications. 12: 5321. PMID 34493732 DOI: 10.1038/s41467-021-25684-3  0.449
2021 Wu S, Fukumoto T, Lin J, Nacarelli T, Wang Y, Ong D, Liu H, Fatkhutdinov N, Zundell JA, Karakashev S, Zhou W, Schwartz LE, Tang HY, Drapkin R, Liu Q, et al. Targeting glutamine dependence through GLS1 inhibition suppresses ARID1A-inactivated clear cell ovarian carcinoma. Nature Cancer. 2: 189-200. PMID 34085048 DOI: 10.1038/s43018-020-00160-x  0.341
2020 Karakashev S, Zhang R. Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors. Molecular & Cellular Oncology. 7: 1760675. PMID 32944622 DOI: 10.1080/23723556.2020.1760675  0.361
2019 Fukumoto T, Fatkhutdinov N, Zundell JA, Tcyganov EN, Nacarelli T, Karakashev S, Wu S, Liu Q, Gabrilovich DI, Zhang R. HDAC6 inhibition synergizes with anti-PD-L1 therapy in ARID1A-inactivated ovarian cancer. Cancer Research. PMID 31311810 DOI: 10.1158/0008-5472.Can-19-1302  0.32
2019 Fukumoto T, Zhu H, Nacarelli T, Karakashev S, Fatkhutdinov N, Wu S, Liu P, Kossenkov AV, Showe LC, Jean S, Zhang L, Zhang R. N6-methylation of adenosine (m6A) of FZD10 mRNA contributes to PARP inhibitor resistance. Cancer Research. PMID 30967398 DOI: 10.1158/0008-5472.Can-18-3592  0.383
2018 Fukumoto T, Park PH, Wu S, Fatkhutdinov N, Karakashev S, Nacarelli T, Kossenkov AV, Speicher DW, Jean S, Zhang L, Wang TL, Shih IM, Conejo-Garcia JR, Bitler BG, Zhang R. Repurposing Pan-HDAC Inhibitors for ARID1A-Mutated Ovarian Cancer. Cell Reports. 22: 3393-3400. PMID 29590609 DOI: 10.1016/J.Celrep.2018.03.019  0.342
2018 Karakashev S, Zhu H, Wu S, Yokoyama Y, Bitler BG, Park PH, Lee JH, Kossenkov AV, Gaonkar KS, Yan H, Drapkin R, Conejo-Garcia JR, Speicher DW, Ordog T, Zhang R. CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nature Communications. 9: 631. PMID 29434212 DOI: 10.1038/S41467-018-03031-3  0.469
2017 Karakashev S, Zhu H, Yokoyama Y, Zhao B, Fatkhutdinov N, Kossenkov AV, Wilson AJ, Simpkins F, Speicher D, Khabele D, Bitler BG, Zhang R. BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian Cancer. Cell Reports. 21: 3398-3405. PMID 29262321 DOI: 10.1016/J.Celrep.2017.11.095  0.424
2017 Karakashev S, Aird KM. Ovarian cancer: how can resistance to chemotherapy be tackled? Future Oncology (London, England). 13: 2737-2739. PMID 29182383 DOI: 10.2217/Fon-2017-0235  0.409
2015 Karakashev SV, Reginato MJ. Progress toward overcoming hypoxia-induced resistance to solid tumor therapy. Cancer Management and Research. 7: 253-64. PMID 26316817 DOI: 10.2147/Cmar.S58285  0.663
2015 Karakashev SV, Reginato MJ. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2. Oncotarget. 6: 1967-80. PMID 25596742 DOI: 10.18632/Oncotarget.2806  0.693
2015 Karakashev S, Reginato M. Abstract 716: Targeting Mek-Erk pathway abrogates hypoxia-mediated lapatinib resistance in ErbB2-positive breast cancer cells Cancer Research. 75: 716-716. DOI: 10.1158/1538-7445.Am2015-716  0.664
2013 Whelan KA, Schwab LP, Karakashev SV, Franchetti L, Johannes GJ, Seagroves TN, Reginato MJ. The oncogene HER2/neu (ERBB2) requires the hypoxia-inducible factor HIF-1 for mammary tumor growth and anoikis resistance. The Journal of Biological Chemistry. 288: 15865-77. PMID 23585570 DOI: 10.1074/Jbc.M112.426999  0.588
2013 Karakashev SV, Mauricio RJ. Abstract PR15: Hypoxia induces lapatinib resistance in ErbB2-positive breast cancer cells via regulation of DUSP2 Cancer Research. 73: 1824-1824. DOI: 10.1158/1538-7445.Fbcr13-Pr15  0.773
Show low-probability matches.